Emtricitabine plus adefovir dipivoxil
ApprovedUNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hepatitis B, Chronic
Conditions
Hepatitis B, Chronic, Fibrosis
Trial Timeline
Jan 1, 2015 → Jul 1, 2017
NCT ID
NCT02327689About Emtricitabine plus adefovir dipivoxil
Emtricitabine plus adefovir dipivoxil is a approved stage product being developed by Pacific Biosciences for Hepatitis B, Chronic. The current trial status is unknown. This product is registered under clinical trial identifier NCT02327689. Target conditions include Hepatitis B, Chronic, Fibrosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02327689 | Approved | UNKNOWN |
Competing Products
20 competing products in Hepatitis B, Chronic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| Pegasys® + Pegasys® | Chugai Pharmaceutical | Approved | 85 |
| peginterferon alfa-2a + rivavirin | Chugai Pharmaceutical | Phase 3 | 77 |
| SOF + COPE | Chugai Pharmaceutical | Pre-clinical | 23 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK788 | Astellas Pharma | Phase 2 | 52 |
| MK-2248 | Merck | Phase 1 | 33 |
| Interferon alfacon-1 | Astellas Pharma | Phase 3 | 77 |
| Pegylated Interferon + Ribavirin | Astellas Pharma | Approved | 85 |
| Tacrolimus + steroids, monoclonal anti-IL2R antibody | Astellas Pharma | Phase 2 | 52 |
| Dolutegravir + Rlipivirine + GSK1265744 | Shionogi | Phase 1 | 33 |
| Dolutegravir + Methadone | Shionogi | Phase 1 | 33 |
| Clevudine + Adefovir | Eisai | Phase 3 | 77 |